iloprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 1422 78919-13-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • iloprost
  • ciloprost
  • endoprost
  • ilomedin
  • ventavis
  • ZK36374
  • ZK-36374
  • ZK 36374
An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.
  • Molecular weight: 360.49
  • Formula: C22H32O4
  • CLOGP: 2.56
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 77.76
  • ALOGS: -4.62
  • ROTB: 9
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 mg Inhal.solution
50 mcg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 16 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.37 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.40 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.57 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK,TGFBR1 19
kinase-selectivity-class MAP2K6 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 2004 FDA ACTELION PHARMS LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 1017.58 20.42 718 13630 455833 90158266
Dyspnoea 351.50 20.42 551 13797 880404 89733695
Right ventricular failure 299 20.42 113 14235 19092 90595007
Fluid retention 190.49 20.42 137 14211 87954 90526145
Pulmonary hypertension 176.86 20.42 100 14248 42423 90571676
Hospitalisation 153.20 20.42 141 14207 127959 90486140
Cardiac failure 145.67 20.42 128 14220 109368 90504731
Cough 120.52 20.42 212 14136 368750 90245349
Oxygen saturation decreased 114.49 20.42 111 14237 107372 90506727
Syncope 93.42 20.42 110 14238 132553 90481546
Dyspnoea exertional 83.30 20.42 78 14270 72210 90541889
Headache 79.25 20.42 307 14041 862439 89751660
Transfusion 77.77 20.42 43 14305 17445 90596654
Hypotension 75.55 20.42 162 14186 325235 90288864
Oedema peripheral 74.92 20.42 141 14207 257774 90356325
Chest pain 74.05 20.42 159 14189 319486 90294613
Product dose omission issue 73.27 20.42 150 14198 291537 90322562
Disease progression 71.57 20.42 105 14243 156510 90457589
Rash 71.49 20.42 19 14329 796081 89818018
Alopecia 59.81 20.42 5 14343 495066 90119033
Pain in jaw 59.58 20.42 54 14294 47931 90566168
Lung transplant 58.42 20.42 22 14326 3670 90610429
Choking 57.41 20.42 31 14317 12002 90602097
Pulmonary arterial hypertension 57.14 20.42 41 14307 26146 90587953
Inappropriate schedule of product administration 56.54 20.42 92 14256 149841 90464258
Hypervolaemia 55.32 20.42 44 14304 32713 90581386
Drug hypersensitivity 52.53 20.42 6 14342 463603 90150496
Catheterisation cardiac 52.14 20.42 22 14326 4934 90609165
Cardiac failure congestive 50.70 20.42 70 14278 98624 90515475
Pulmonary arterial pressure increased 50.11 20.42 20 14328 3896 90610203
Asphyxia 47.56 20.42 23 14325 7080 90607019
Multiple epiphyseal dysplasia 47.50 20.42 9 14339 98 90614001
Skeletal dysplasia 46.70 20.42 9 14339 108 90613991
Pulmonary oedema 46.20 20.42 53 14295 62027 90552072
Cyanosis 46.01 20.42 32 14316 19423 90594676
Epistaxis 44.66 20.42 61 14287 85064 90529035
N-terminal prohormone brain natriuretic peptide increased 44.52 20.42 17 14331 2945 90611154
Joint swelling 43.27 20.42 13 14335 503287 90110812
Cardiac arrest 43.13 20.42 67 14281 104868 90509231
Nasal congestion 41.10 20.42 58 14290 83356 90530743
Arthropathy 40.83 20.42 5 14343 366237 90247862
Brachydactyly 40.40 20.42 9 14339 227 90613872
Haemoptysis 40.38 20.42 37 14311 33283 90580816
Rheumatoid arthritis 40.30 20.42 5 14343 362609 90251490
Choking sensation 39.81 20.42 17 14331 3925 90610174
Respiratory failure 39.75 20.42 69 14279 118349 90495750
Premature delivery 39.30 20.42 39 14309 38723 90575376
Cardiac disorder 38.08 20.42 46 14302 56826 90557273
Disease complication 37.22 20.42 16 14332 3756 90610343
Concomitant disease aggravated 37.14 20.42 23 14325 11495 90602604
Walking distance test abnormal 36.78 20.42 10 14338 583 90613516
Product cleaning inadequate 36.28 20.42 6 14342 27 90614072
Urticaria 35.52 20.42 4 14344 312730 90301369
Influenza 35.34 20.42 72 14276 139192 90474907
Cardiac pacemaker insertion 34.83 20.42 16 14332 4391 90609708
Oedema 34.67 20.42 89 14259 200206 90413893
Dizziness 34.55 20.42 184 14164 589100 90024999
Treatment failure 34.24 20.42 4 14344 303924 90310175
Right ventricular dilatation 33.85 20.42 12 14336 1687 90612412
Caesarean section 33.62 20.42 26 14322 18551 90595548
Hypersensitivity 33.57 20.42 15 14333 454662 90159437
Hepatic enzyme increased 33.47 20.42 8 14340 360728 90253371
Cardiomegaly 33.20 20.42 26 14322 18899 90595200
Scleroderma 32.32 20.42 17 14331 6244 90607855
Glossodynia 32.18 20.42 6 14342 321773 90292326
Pericarditis 31.85 20.42 3 14345 270148 90343951
Systemic scleroderma 30.81 20.42 11 14337 1578 90612521
Product supply issue 30.54 20.42 13 14335 2979 90611120
Therapeutic product effect decreased 30.41 20.42 4 14344 277567 90336532
Arthralgia 30.19 20.42 48 14300 778474 89835625
Neonatal respiratory distress syndrome 30.09 20.42 13 14335 3088 90611011
Foetal exposure timing unspecified 29.86 20.42 8 14340 441 90613658
Pulmonary hypertensive crisis 29.38 20.42 8 14340 469 90613630
Device malfunction 28.80 20.42 25 14323 20952 90593147
Drug delivery system malfunction 28.45 20.42 10 14338 1371 90612728
Posture abnormal 28.40 20.42 12 14336 2699 90611400
Treatment noncompliance 27.02 20.42 37 14311 51690 90562409
Blood carbon monoxide increased 26.96 20.42 4 14344 7 90614092
Hypertension 26.79 20.42 20 14328 457512 90156587
Exercise tolerance decreased 26.71 20.42 16 14332 7535 90606564
Hypoxia 26.69 20.42 44 14304 72355 90541744
Contraindicated product administered 26.19 20.42 9 14339 320130 90293969
Wound 25.69 20.42 8 14340 302972 90311127
Unevaluable event 25.34 20.42 37 14311 54811 90559288
Pneumonia 25.22 20.42 180 14168 637879 89976220
Abdominal cavity drainage 25.03 20.42 7 14341 453 90613646
Blister 24.97 20.42 5 14343 254993 90359106
Vascular resistance pulmonary decreased 24.91 20.42 5 14343 75 90614024
Duodenal ulcer perforation 24.70 20.42 3 14345 221285 90392814
Flushing 23.94 20.42 47 14301 88444 90525655
Confusional state 23.76 20.42 16 14332 386189 90227910
Toxicity to various agents 23.70 20.42 8 14340 287838 90326261
Systemic lupus erythematosus 23.63 20.42 14 14334 361882 90252217
Cardiopulmonary failure 23.42 20.42 12 14336 4176 90609923
Product prescribing issue 23.39 20.42 15 14333 7964 90606135
Asthma 23.19 20.42 5 14343 242155 90371944
Ventricular assist device insertion 23.09 20.42 4 14344 25 90614074
Blood cholesterol increased 22.78 20.42 3 14345 208009 90406090
Mouth haemorrhage 22.52 20.42 15 14333 8486 90605613
Finger amputation 22.46 20.42 7 14341 661 90613438
Device use error 22.22 20.42 14 14334 7207 90606892
Respiratory distress 22.08 20.42 29 14319 38917 90575182
Drug intolerance 22.06 20.42 23 14325 447568 90166531
Palpitations 21.85 20.42 59 14289 136669 90477430
Cardio-respiratory arrest 21.44 20.42 37 14311 63103 90550996
Premature baby 21.39 20.42 23 14325 25054 90589045
Throat irritation 21.28 20.42 32 14316 48663 90565436
Injury 21.24 20.42 3 14345 197346 90416753
Productive cough 20.93 20.42 41 14307 77022 90537077
Product use issue 20.65 20.42 105 14243 329814 90284285

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 655.98 28.02 449 3564 470736 42146586
Right ventricular failure 164.27 28.02 53 3960 9502 42607820
Fluid retention 91.49 28.02 49 3964 31570 42585752
Dyspnoea 89.23 28.02 153 3860 442468 42174854
Pulmonary hypertension 86.88 28.02 43 3970 23526 42593796
Hospitalisation 57.53 28.02 51 3962 74279 42543043
Oxygen saturation decreased 41.52 28.02 40 3973 64647 42552675
Cough 37.42 28.02 63 3950 178040 42439282
Neonatal pneumonia 37.20 28.02 7 4006 128 42617194
Spontaneous intrahepatic portosystemic venous shunt 34.43 28.02 5 4008 15 42617307
Neonatal hypotension 34.18 28.02 7 4006 201 42617121
Product use issue 34.10 28.02 39 3974 76712 42540610
Cardiac index increased 32.40 28.02 5 4008 25 42617297
Flushing 31.82 28.02 27 3986 37001 42580321
Oedema 29.36 28.02 30 3983 51971 42565351
Pulmonary vascular resistance abnormality 28.17 28.02 5 4008 65 42617257

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 1036.57 20.35 859 16466 698010 109873964
Right ventricular failure 421.36 20.35 157 17168 25797 110546177
Dyspnoea 413.51 20.35 668 16657 1106204 109465770
Fluid retention 278.08 20.35 177 17148 94130 110477844
Pulmonary hypertension 231.36 20.35 130 17195 55090 110516884
Cough 151.23 20.35 264 17061 461377 110110597
Oxygen saturation decreased 137.28 20.35 145 17180 156837 110415137
Hospitalisation 136.10 20.35 138 17187 142355 110429619
Cardiac failure 121.03 20.35 148 17177 187478 110384496
Headache 112.81 20.35 348 16977 882029 109689945
Transfusion 95.99 20.35 56 17269 25416 110546558
Syncope 93.98 20.35 136 17189 202400 110369574
Pain in jaw 89.81 20.35 70 17255 51107 110520867
Dyspnoea exertional 88.93 20.35 95 17230 103965 110468009
Oedema peripheral 88.58 20.35 173 17152 328487 110243487
Chest pain 85.96 20.35 185 17140 376190 110195784
Catheterisation cardiac 77.40 20.35 31 17294 6160 110565814
Product dose omission issue 73.25 20.35 158 17167 321624 110250350
Pulmonary arterial hypertension 64.75 20.35 48 17277 32520 110539454
Lung transplant 64.46 20.35 26 17299 5260 110566714
Choking 64.39 20.35 36 17289 15074 110556900
Disease progression 62.73 20.35 126 17199 243908 110328066
Oedema 60.77 20.35 114 17211 209862 110362112
Pulmonary arterial pressure increased 58.35 20.35 24 17301 5103 110566871
Inappropriate schedule of product administration 53.34 20.35 106 17219 203531 110368443
Hypervolaemia 51.03 20.35 50 17275 49410 110522564
Rash 50.99 20.35 33 17292 820931 109751043
Drug hypersensitivity 50.42 20.35 6 17319 454084 110117890
Epistaxis 49.75 20.35 80 17245 130292 110441682
Concomitant disease aggravated 48.86 20.35 31 17294 16333 110555641
Cardiac failure congestive 48.77 20.35 86 17239 150914 110421060
Drug delivery system malfunction 48.58 20.35 14 17311 1021 110570953
Neutropenia 46.86 20.35 3 17322 374617 110197357
Product use issue 46.32 20.35 130 17195 311565 110260409
Hypotension 45.32 20.35 182 17143 523667 110048307
Dizziness 44.89 20.35 222 17103 697971 109874003
Flushing 43.75 20.35 67 17258 104669 110467305
Premature delivery 43.40 20.35 37 17288 30595 110541379
Pulmonary vascular resistance abnormality 41.37 20.35 9 17316 205 110571769
Toxicity to various agents 41.36 20.35 12 17313 480543 110091431
Haemoptysis 40.71 20.35 53 17272 71301 110500673
Pulmonary oedema 40.09 20.35 63 17262 100596 110471378
Nasal congestion 39.82 20.35 62 17263 98220 110473754
Pulmonary hypertensive crisis 39.47 20.35 10 17315 447 110571527
Cardiac disorder 39.45 20.35 54 17271 76226 110495748
Caesarean section 38.35 20.35 25 17300 13792 110558182
Asphyxia 37.70 20.35 25 17300 14190 110557784
Alopecia 37.70 20.35 6 17319 364747 110207227
Disease complication 36.59 20.35 18 17307 5809 110566165
Mouth haemorrhage 36.45 20.35 24 17301 13464 110558510
Exercise tolerance decreased 36.37 20.35 23 17302 12044 110559930
N-terminal prohormone brain natriuretic peptide increased 35.75 20.35 18 17307 6103 110565871
Cardiac pacemaker insertion 35.26 20.35 18 17307 6283 110565691
Influenza 34.99 20.35 80 17245 169021 110402953
Choking sensation 34.89 20.35 16 17309 4420 110567554
Walking distance test abnormal 34.61 20.35 10 17315 736 110571238
Throat irritation 34.07 20.35 42 17283 53510 110518464
Product cleaning inadequate 33.32 20.35 5 17320 10 110571964
Confusional state 33.14 20.35 16 17309 468664 110103310
Respiratory failure 33.13 20.35 91 17234 215241 110356733
Musculoskeletal stiffness 32.84 20.35 3 17322 279819 110292155
Acute kidney injury 32.52 20.35 31 17294 635399 109936575
Spontaneous intrahepatic portosystemic venous shunt 31.88 20.35 5 17320 15 110571959
Rheumatoid arthritis 30.79 20.35 5 17320 299608 110272366
Device malfunction 30.48 20.35 28 17297 25530 110546444
Right ventricular dilatation 30 20.35 12 17313 2375 110569599
Cardiac index increased 28.94 20.35 5 17320 31 110571943
Neonatal pneumonia 28.67 20.35 5 17320 33 110571941
Pneumonia 28.30 20.35 234 17091 876480 109695494
Hypersensitivity 28.24 20.35 14 17311 403984 110167990
Treatment noncompliance 28.12 20.35 45 17280 72945 110499029
Brain natriuretic peptide increased 28.01 20.35 19 17306 11190 110560784
Product supply issue 27.73 20.35 13 17312 3773 110568201
Therapeutic product effect decreased 27.67 20.35 3 17322 244313 110327661
Drug administered in wrong device 27.57 20.35 6 17319 137 110571837
Premature baby 27.54 20.35 14 17311 4841 110567133
Neonatal hypotension 27.40 20.35 5 17320 44 110571930
Joint swelling 27.17 20.35 18 17307 442827 110129147
Ventricular assist device insertion 26.65 20.35 5 17320 52 110571922
Cardio-respiratory arrest 26.43 20.35 57 17268 115779 110456195
Sudden death 25.79 20.35 25 17300 24370 110547604
Transplant evaluation 25.78 20.35 10 17315 1825 110570149
Respiratory disorder neonatal 25.77 20.35 5 17320 63 110571911
Treatment failure 25.60 20.35 6 17319 277228 110294746
Cardiomegaly 25.58 20.35 27 17298 29103 110542871
Urticaria 25.58 20.35 9 17316 318848 110253126
Systemic scleroderma 25.08 20.35 10 17315 1962 110570012
Arthropathy 25.05 20.35 7 17318 287515 110284459
Vascular resistance pulmonary decreased 24.83 20.35 5 17320 77 110571897
Cardiac operation 24.77 20.35 14 17311 5981 110565993
Cardiac arrest 24.38 20.35 77 17248 196676 110375298
Atrial septal defect repair 24.30 20.35 7 17318 510 110571464
Arthralgia 24.20 20.35 54 17271 779578 109792396
Device use error 24.14 20.35 16 17309 9073 110562901
Pericarditis 24.04 20.35 3 17322 219111 110352863
Product use in unapproved indication 23.85 20.35 21 17304 447356 110124618
Overdose 23.80 20.35 4 17321 233790 110338184
Hypertension 23.69 20.35 27 17298 510057 110061917
Drug dose omission by device 23.62 20.35 19 17306 14497 110557477
Condition aggravated 23.61 20.35 196 17129 734640 109837334
Incorrect product administration duration 23.56 20.35 22 17303 20476 110551498
Cyanosis 23.37 20.35 26 17299 29715 110542259
Vascular resistance pulmonary increased 22.98 20.35 5 17320 114 110571860
Hepatic enzyme increased 22.60 20.35 11 17314 320881 110251093
Malaise 22.55 20.35 181 17144 671638 109900336
Palpitations 22.25 20.35 65 17260 159147 110412827
Concomitant disease progression 22.22 20.35 11 17314 3599 110568375
C-reactive protein increased 21.59 20.35 4 17321 217915 110354059
Scleroderma 21.43 20.35 13 17312 6328 110565646
Product prescribing issue 21.38 20.35 17 17308 12755 110559219
Product administered to patient of inappropriate age 20.99 20.35 14 17311 8022 110563952
Pulmonary veno-occlusive disease 20.92 20.35 9 17316 2139 110569835
Chest discomfort 20.59 20.35 67 17258 173781 110398193
Abdominal cavity drainage 20.39 20.35 7 17318 904 110571070
Left-to-right cardiac shunt 20.37 20.35 5 17320 196 110571778

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AC11 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
FDA CS M0017817 Prostaglandins I
FDA EPC N0000175603 Prostacycline
MeSH PA D002317 Cardiovascular Agents
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:50427 platelet aggregation inhibitor
CHEBI has role CHEBI:65023 anti-asthmatic agent

Related Drugs by ATC class:

B01AC Platelet aggregation inhibitors excl. heparin 24 drugs
abciximabacetylsalicylic acidaloxiprinberaprostcangrelorcarbasalate calciumcilostazolclopidogrelcloricromendipyridamoleditazoleepoprostenol show all 24 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pulmonary arterial hypertension indication 11399002
Bronchospasm contraindication 4386001
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Pulmonary edema contraindication 19242006 DOID:11396
Low blood pressure contraindication 45007003
Hepatic failure contraindication 59927004
Mild to Moderate Hypotension contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.83 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MCG/ML (100MCG/ML) AURLUMYN BTG INTL N217933 Feb. 13, 2024 RX SOLUTION INTRAVENOUS 12409183 July 18, 2044 TREATMENT OF SEVERE FROSTBITE IN ADULTS TO REDUCE THE RISK OF DIGIT AMPUTATIONS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MCG/ML (100MCG/ML) AURLUMYN BTG INTL N217933 Feb. 13, 2024 RX SOLUTION INTRAVENOUS Feb. 13, 2027 NEW PRODUCT
100MCG/ML (100MCG/ML) AURLUMYN BTG INTL N217933 Feb. 13, 2024 RX SOLUTION INTRAVENOUS Feb. 13, 2031 TREATMENT OF SEVERE FROSTBITE IN ADULTS TO REDUCE THE RISK OF DIGIT AMPUTATIONS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostacyclin receptor GPCR AGONIST EC50 7.75 WOMBAT-PK CHEMBL
Prostaglandin E2 receptor EP3 subtype GPCR EC50 7.30 WOMBAT-PK
Thromboxane A2 receptor GPCR AGONIST Ki 5.20 IUPHAR
Prostaglandin E2 receptor EP2 subtype GPCR AGONIST Ki 5.70 IUPHAR
Prostaglandin E2 receptor EP4 subtype GPCR AGONIST Ki 6.68 IUPHAR
Prostaglandin D2 receptor GPCR AGONIST Ki 6.60 IUPHAR
Prostaglandin F2-alpha receptor GPCR AGONIST Ki 6.20 IUPHAR
Prostaglandin E2 receptor EP1 subtype GPCR EC50 7.70 WOMBAT-PK
Prostaglandin E2 receptor EP1 subtype GPCR AGONIST Ki 7.70 IUPHAR
Prostaglandin E2 receptor EP2 subtype GPCR AGONIST Ki 5.80 IUPHAR
Prostaglandin E2 receptor EP3 subtype GPCR AGONIST Ki 7.66 IUPHAR
Prostaglandin E2 receptor EP4 subtype GPCR AGONIST Ki 5.60 IUPHAR
Prostaglandin E2 receptor EP2 subtype GPCR AGONIST Ki 5.90 IUPHAR
Prostacyclin receptor GPCR AGONIST Ki 8 IUPHAR
Prostacyclin receptor GPCR EC50 9.16 CHEMBL
Prostaglandin E2 receptor EP3 subtype GPCR AGONIST EC50 9.20 IUPHAR
Prostaglandin E2 receptor EP1 subtype GPCR AGONIST Ki 7.90 IUPHAR

External reference:

IDSource
4024905 VUID
N0000171024 NUI
D02721 KEGG_DRUG
4024905 VANDF
C0079594 UMLSCUI
CHEBI:63916 CHEBI
CHEMBL494 ChEMBL_ID
DB01088 DRUGBANK_ID
CHEMBL5315118 ChEMBL_ID
D016285 MESH_DESCRIPTOR_UI
5311181 PUBCHEM_CID
1895 IUPHAR_LIGAND_ID
4972 INN_ID
JED5K35YGL UNII
40138 RXNORM
19138 MMSL
52233 MMSL
64085 MMSL
d05232 MMSL
005258 NDDF
319452005 SNOMEDCT_US
395740002 SNOMEDCT_US
JED5K35YGL INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AURLUMYN HUMAN PRESCRIPTION DRUG LABEL 1 50633-340 INJECTION, SOLUTION 100 ug INTRAVENOUS NDA 27 sections